Tower Research Capital (TRC)’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-610
| Closed | -$44K | – | 5496 |
|
|
2025
Q4 | $44K | Sell |
610
-3,070
| -83% | -$198K | ﹤0.01% | 2519 |
|
|
2025
Q3 | $160K | Sell |
3,680
-9,329
| -72% | -$377K | ﹤0.01% | 1643 |
|
|
2025
Q2 | $369K | Buy |
13,009
+4,850
| +59% | +$145K | 0.01% | 1232 |
|
|
2025
Q1 | $241K | Sell |
8,159
-17,870
| -69% | -$557K | 0.01% | 1259 |
|
|
2024
Q4 | $757K | Buy |
26,029
+24,815
| +2,044% | +$1.04M | 0.02% | 795 |
|
|
2024
Q3 | $55.8K | Sell |
1,214
-16,114
| -93% | -$699K | ﹤0.01% | 2665 |
|
|
2024
Q2 | $708K | Buy |
17,328
+16,679
| +2,570% | +$479K | 0.01% | 1036 |
|
|
2024
Q1 | $16.6K | Sell |
649
-20,909
| -97% | -$328K | ﹤0.01% | 3171 |
|
|
2023
Q4 | $195K | Buy |
21,558
+18,533
| +613% | +$124K | ﹤0.01% | 2114 |
|
|
2023
Q3 | $19.3K | Sell |
3,025
-12,545
| -81% | -$108K | ﹤0.01% | 3412 |
|
|
2023
Q2 | $173K | Buy |
15,570
+8,930
| +134% | +$112K | 0.01% | 1658 |
|
|
2023
Q1 | $102K | Sell |
6,640
-11,362
| -63% | -$250K | ﹤0.01% | 1851 |
|
|
2022
Q4 | $400K | Buy |
18,002
+7,716
| +75% | +$115K | 0.02% | 830 |
|
|
2022
Q3 | $168K | Sell |
10,286
-727
| -7% | -$13.9K | ﹤0.01% | 2093 |
|
|
2022
Q2 | $160K | Buy |
11,013
+9,620
| +691% | +$143K | ﹤0.01% | 1936 |
|
|
2022
Q1 | $26K | Sell |
1,393
-3,067
| -69% | -$52.1K | ﹤0.01% | 3291 |
|
|
2021
Q4 | $106K | Buy |
4,460
+3,500
| +365% | +$83.6K | ﹤0.01% | 2185 |
|
|
2021
Q3 | $24K | Sell |
960
-5,514
| -85% | -$120K | ﹤0.01% | 3567 |
|
|
2021
Q2 | $160K | Buy |
6,474
+5,056
| +357% | +$118K | ﹤0.01% | 2086 |
|
|
2021
Q1 | $31K | Buy |
1,418
+300
| +27% | +$7.34K | ﹤0.01% | 3543 |
|
|
2020
Q4 | $29K | Sell |
1,118
-1,510
| -57% | -$44K | ﹤0.01% | 3604 |
|
|
2020
Q3 | $74K | Buy |
+2,628
| New | +$76K | ﹤0.01% | 3364 |
|
Other funds holding RNAM
Tower Research Capital (TRC)'s RNAM Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 610 shares — an estimated $44K sold.
Tower Research Capital (TRC) first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $757K in Q4 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 610 Avidity Biosciences shares in Q1 2026, an estimated $44K.
- Tower Research Capital (TRC) first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Tower Research Capital (TRC)'s Avidity Biosciences position peaked at $757K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.